Click here for slides on this topic


Fibrates

Class of lipid-lowering agents.
The following content matched the glossary term: Fibrates

AACE 2015 guidelines Cardiovascular Disease Management

Top

Summary of recommendations for managing cardiovascular disease (CVD), including dyslipidemia and hypertension, from the 2015 AACE diabetes guidelines 

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Triglycerides_Spanish

Top

 

Patient education handout exploring appropriate triglyceride levels and targets—in Spanish.

Triglycerides

Top

 

Patient education handout exploring appropriate triglyceride levels and targets.

Cholesterol_Spanish

Top

 

Patient education handout exploring appropriate cholesterol levels and targets—in Spanish.

Cholesterol

Top

 

Patient education handout exploring appropriate cholesterol levels and targets.

Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction

Top

Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction OBJECTIVE: Patients with diabetes remain at high risk for cardiovascular events despite aggressive blood pressure, LDL cholesterol, and blood glucose co

What is the most effective strategy for managing diabetic dyslipidaemia?

Top

Reasner CA. What is the most effective strategy for managing diabetic dyslipidemia? Atheroscler Suppl. 2005;6:21-27. The dyslipidaemic profile of diabetes greatly contributes to the increased cardiovascular risk associated with the disorder, and evidence from many intervention trials using statins, fibrates, nicotinic acid or a nicotinic acid-statin combination, indicates the substantial cardiovascular risk reduction to be gained from lipid modification.

Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus : focus on lipid-regulating therapy

Top

Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus : focus on lipid-regulating therapy. Drugs. 2005;65:31-74. Endothelial dysfunction and increased arterial stiffness occur early in the pathogenesis of diabetic vasculopathy. They are both powerful independent predictors of cardiovascular risk.

Variation in the PPAR-a Gene Is Associated With Altered Function In Vitro and Plasma Lipid Concentrations in Type 2 Diabetic Subjects

Top

Flavell DM, Torra IP, Jamshidi Y, et al. Variation in the PPAR-Alpha Gene Is Associated With Altered Function In Vitro and Plasma Lipid Concentrations in Type 2 Diabetic Subjects. Diabetologia. 2000;43:673-680. Peroxisome proliferator activated receptor-a (PPAR-a) regulates genes involved in lipid metabolism, haemostasis and inflammation, in response to fatty acids and fibrates, making it a candidate gene for risk of dyslipidaemia, atherosclerosis and coronary artery disease.

1 2 Next 

Slide Library Results

Search Results for: Fibrates Slides Found: 8
Effect of the Atkins Diet on Weight, Lipids, and Insulin
PPARa and HDL Metabolism (animated)
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI